Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma [version 1; referees: awaiting peer review] by Díaz-Castellanos, Miguel-Ángel et al.
 Open Peer Review
Discuss this article
 (0)Comments
CASE REPORT
Case Report: Propranolol increases the therapeutic response to
 temozolomide in a patient with metastatic paraganglioma
[version 1; referees: awaiting peer review]
Miguel-Angel Díaz-Castellanos ,   Karina Villar Gómez de las Heras ,
     Tamara Díaz-Redondo , Encarnación González-Flores , Virginia Albiñana ,
Luisa-María Botella 6
PHEiPAS, Castellón de la Plana, 12006, Spain
Alianza VHL, Centro Cívico Rogelio Soto, Sabadell, 08204, Spain
Sanidad Castilla-La Mancha, Toledo, Spain
Servicio de Oncología, Hospital Universitario Carlos Haya, Málaga, 29010, Spain
Servicio de Oncología, Hospital Universitario Virgen de las Nieves, Granada, 18014, Spain
Centro de Investigaciones Biológicas, U-707 CIBERER, Madrid, Spain
Abstract
This case report presents the clinical evolution and management of a patient
with a hereditary paraganglioma syndrome. This disease is characterized by
rare tumors of neural crest origin that are symmetrically distributed along the
paravertebral axis from the base of the skull and neck to the pelvis. In addition,
these patients may develop renal cancer, gastrointestinal stromal tumors,
pituitary adenomas, and bone metastasis in some cases. To date no successful
therapeutic treatment has been reported. Total resection with postoperative
radiotherapy and chemotherapy have been advocated, especially for the
multiple metastasis. Here we show how the combination of high doses of the
beta blocker propranolol (3 mg/Kg/day) and the DNA intercalating agent,
temozolomide, has been successful in the treatment of a SDHA metastatic
paraganglioma.
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Introduction
Hereditary paraganglioma and pheochromocytoma syndromes 
(HPP) are characterized by rare tumors called pheochromocyto-
mas (PHEOs) and paragangliomas (PGLs). These are highly vas-
cularized catecholamine-secreting tumors of neural crest origin 
(chromaffin cells derived from the adrenal medulla – pheochromo-
cytoma – or extra-adrenal paraganglia - paragangliomas), distrib-
uted symmetrically along the paravertebral axis. Although tumors 
are usually histologically benign, most of them hyper-secrete cat-
echolamines, causing high cardiovascular morbidity and mortality1, 
and symptoms related to mass effect. If left untreated, a subset of 
these tumors will metastasize in bones, lungs, liver or lymph nodes2. 
These patients can develop other rare tumors too, such as renal 
cancer and gastrointestinal stromal tumors. However, tumorigen-
esis is rare in the first decade of life.
HPP syndromes are due to pathogenic variants of genes, SDHx 
genes, a group of multiple nuclear genes encoding subunits of 
the succinate dehydrogenase (SDH) enzyme complex. Similarly 
to other autosomal-dominant hereditary cancer disease - von 
Hippel-Lindau (VHL) -paraganglioma–pheochromocytoma (PGL/
PCC) syndrome is related to the hypoxia pathway3. Hypoxia-
inducible factor 1 (HIF1) regulates the cellular response according 
to oxygen levels. HIF is a heterodimer of a HIF1-α subunit, reg-
ulated by oxygenation and a β subunit. Under normal oxygen 
conditions, HIF1-α degradation is promoted by the E3 ubiquitin 
ligase pVHL (von Hippel Lindau factor). In lower oxygen cell 
environments, VHL recognition of HIF-1α is decreased, allow-
ing HIF1 to promote cellular survival and growth4. In cancer, the 
hypoxia pathway is switched by the tumoral cells leading to the 
tumor growth5. Pseudo-hypoxic states are those leading to the 
hypoxia-pathway gene expression, under normoxic conditions.
Germline mutations in the onco-suppressor gene, called Vhl 
leads to the autosomal-dominant hereditary cancer disease VHL. 
VHL disease is clinically characterized by retinal and CNS 
hemangioblastomas, RCC (renal clear cell carcinoma), PCC, 
neuroendocrine pancreatic tumors and pancreatic cystadenomas, 
endolymphatic sac tumors and broad ligament cystadenomas. 
Closely related to this disease are the mutations involving the suc-
cinate dehydrogenase genes (SDHx genes)6. The lack of function 
of SDHx genes leads to an inhibition of prolyl hydroxylases by 
alpha-ketoglutarate. These hydroxylases “target” HIF1/2-α by 
specific hydroxylation to be recognized and bound by VHL. In this 
way, hydroxylases cannot help in the degradation of HIF, and a 
state of pseudo-hypoxia7 is created. Thus, pseudo-hypoxic states 
display similar hypoxia-pathway triggered gene expression, but 
under normoxic conditions.
Surveillance recommendations for both diseases (VHL disease and 
PHEO/PGL)2 are very similar. It is important to suspect, localize 
and resect these tumors.
The present case presents the clinical evolution and manage-
ment of a patient with a hereditary paraganglioma syndrome. The 
combination of high doses of the beta blocker propranolol 
(3 mg/Kg/day) and the DNA intercalating agent, temozolomide, 
was been successful in the treatment of the SDHA metastatic 
paraganglioma.
Case description
A 53 year old man, with personal and family history of hyper-
tension, was diagnosed with a 4 cm tumoral mass at costover-
tebral D6–D7 with a 21 max SUV, during a routine check-up in 
March 2010. The only manifestation of disease was elevated 
blood pressure. He was being treated at this time with irbesartan/ 
hydrochlorothiazide (1250mg/12.5mg, respectively). After surgery, 
the pathology diagnosis was of PGL with a Ki67 around 5-8%, 
and synaptophysin and chromogranin positive. Genetic analysis 
found a mutation in the SDHA gene, leading to a heterozygous mis-
sense p.Ser445Leu change, defined as pathogenic8. The patient 
remained without treatment and symptom-free until August 2014, 
when a back pain appeared around the D10 region, with progressive 
worsening. In October, as the pain persisted, he underwent MRI 
and 18F-DG-PET scan and was diagnosed with several metasta-
sis at: D6–D7, right acetabulum (3cm); vertebral hemi-body D10 
(3cm); vertebral body of D12 (2cm); and left iliac crest (1cm). 
A scintigraphy with Indium-111 pentetreotide suggested meta-
static disease of probably neuroendocrine origin. D10 lesion biopsy 
confirmed the diagnosis of PGL metastasis with a Ki67 around 
15–20% (Figure 1A). The patient was treated with doxazosin 
(8 mg/day) and bisoprolol (10 mg/day).
In November 2014, the patient started on systemic treatment 
with denosumab (120 mg every 28 days) and lanreotide (120 mg 
every 14 days). After 4 months, a PET-TAC showed a metabolic 
stabilization of the disease, but with a slight growth of lesions 
according to MRI (Figure 1B). D6 and D10 lesions were then 
treated by radiotherapy (Cyberknife). To this purpose, in March/
April 2015 the patient underwent SBRT with CiberKnife (24 Gy 
in D10, 15 Gy in D12 and 35 Gy in D6–7), and the pain 
disappeared. After 6 months, the D7 and D12 lesions were also 
irradiated and completed SBRT with CiberKnife (24 Gy in left 
iliac bone and 24 Gy to right acetabulum).
Response to radiotherapy was good, showing stability of lesions 
and decrease of max SUV. No new lesions appeared. In June 2015, 
a thermoablation and right acetabulum metastasis cementation 
was performed with good results.
At this moment, the anti-hypertensive bisoprolol was changed 
to propranolol(120mg/day), due to preliminary reports of pro-
pranolol’s good results in VHL tumors9. During the following 
11 months, the patient remained stable without disease progres-
sion (Figure 1C). Lanreotide dose was decreased to 120 mg every 
3 weeks, due to side effects. Side effects included nausea, vomits, 
diarrhea and hyperglycaemia.
In May 2016, metanephrines and chromogranin were raised 
above normal levels, as follows: Chromogranin A, 106 ng/mL 
(normal level, <93); urine fractionated Norepinephrine, 
196 mcg/24h (normal levels, 15–80); urine fractionated norme-
tanephrine, 1316 mcg/24 h (normal levels, 128-484); urine total 
metanephephrine, 1394 mcg/24h (normal levels, 220-680). 
A 18FDG-PET-TAC revealed an important metastatic dissemina-
tion all over the skeleton, showing more than 40 small new lesions 
less than 2 cm, and with scarce or null Octreoscan and 123I-MIBG 
uptake (Figure 1D).
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Figure 1. MRI and 18F-DG-PET scan. (A) In October 2014, several metastasis at D6–D7, right acetabulum (3cm); vertebral hemi-body D10 
(3cm); vertebral body of D12 (2cm); and left iliac crest (1cm) were observed. (B) 4 months later, a PET-TAC showed a metabolic stabilization 
of the disease, but with a slight growth of lesions according to MRI. (C) During the following 11 months, the patient remained stable without 
disease progression. (D) In May 2016, a 18 FDG-PET-TAC revealed an important metastatic dissemination all over the skeleton, showing more 
than 40 small new lesions (<2 cm), and with scarce or null Octreoscan and 123I-MIBG uptake. (E) In December 2016, most of lesions had 
disappeared according to PET-TAC. (F) In July 2017, a new PET supported the previous results, showing the remaining two lesions but with 
maximum SUV lower. (G) In October 2017, 4 months since the last dose of temozolomide, and propranolol as the only treatment (240mg/day), 
the disease remains controlled according to this last PET-TAC.
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From this moment on, a combined treatment of temozolomide 
(75 mg/m² for 21 days every 28 days) and an increase of pro-
pranolol up to 3 mg/kg/day (240 mg/day) was prescribed. After 
the first cycle of temozolomide, results were evaluated in August 
2016 at National Institutes of Health, where the previously detected 
metastatic dissemination was confirmed, although catecholamines 
and chromogranin levels were decreasing compared with the 
previous measures. Treatment was kept the same for 6 cycles of 
temozolomide. In December 2016, most of lesions had disappeared 
according to PET-TAC (Figure 1E). The two remaining lesions 
had maximum SUV significantly decreased. In January 2017, 
lanreotide was retired due to adverse side effects (as before).
In July 2017, a new PET supported the previous results, show-
ing the remaining two lesions but with maximum SUV lower 
(Figure 1F). Temozolomide was withdrawn because of side effects 
(lymphopenia and thrombopenia). In October 2017, 4 months since 
the last dose of temozolomide, and propranolol as the only treat-
ment (240mg/day), the disease remains controlled according to the 
last PET-TAC (F18-FDG) (Figure 1G). This imaging study suggests 
the presence of two neoplastic bone lesions in the dorsal spine and 
right acetabulum; regarding the previous examination (July 2017), 
the lesions described in D6 and acetabulum persist without major 
changes, whereas that of vertebra D10 has disappeared.
Discussion
The present case report describes an impressive clinical and 
metabolic improvement of a patient suffering from a metastatic 
paraganglioma after using a combination of temozolomide and 
propranolol at high doses. The improvement has been kept even 
after 7 months of lanreotide removal (usually used as standard 
treatment).
We can only hypothesize about the reason for this spectacular 
result. However, there are some literature reports on the synergy 
between chemotherapeutic agents inducing DNA damage, and 
therefore blocking DNA replication (as it is here the case of temo-
zolomide) and β-blockers, which have shown antiangiogenic and 
pro-apoptotic effects in tumoral cells9,10.
Recent examples of these combinations found in the literature 
include the action of β-blockers increasing response to different 
chemotherapeutic agents. Pasquier et al. used a mouse model of 
neuroblastoma, where β-blockers were shown to increase treat-
ment efficacy11. Propranolol in combination with vinblastine 
(chemotherapeutic agent belonging to the group of vegetable 
alkaloids), proved to be a successful treatment for advanced 
angiosarcoma12, with optimal results in seven patients following a 
clinical trial13. Chow et al. showed the regression of a rapidly  
enlarging stage T2 angiosarcoma of the scalp and face, following 
combination therapy with propranolol hydrochloride, paclitaxel 
(other vegetable alkaloid), and radiotherapy14. More recently, 
a prospective study using propranolol for off-label treatment 
of patients with melanoma, confirmed a significantly inversely 
association with recurrence of melanoma when propranolol was 
used at the time of diagnosis15. We could infer that propranolol 
seems to potentiate the anti-angiogenic effects and antitumor 
efficacy of chemotherapy.
Focusing our attention to propranolol- an unspecific β-blocker - as 
an antitumoral agent, Albiñana and coworkers16 recently published 
the clinical and biomarker follow-up of a clinical trial conducted 
in seven VHL patients with retinal hemangioblastomas. These 
patients had no surgical option, and the tumors remained stable in 
size (with reabsorption of exudates) following 120 mg propranolol 
treatment for 12 months. This clinical trial led recently to the 
European Medicines Agency’s designation of propranolol as 
Orphan drug for VHL disease.
The hypothesis supporting the antiangiogenic properties of pro-
pranolol relies on its proven effect on decreasing HIF-inducible 
transcription targets9. Propranolol would decrease HIF protein lev-
els, and therefore, the activation of the hypoxia program developed 
by the hypoxia target genes, among them, angiogenic factors, such 
as VEGF, FGF, PDGF, EPO, and metalloproteases, activated in 
tumors that favor migration and dissemination of cancer cells.
The advantages of the use of propranolol and temozolomide derive 
mainly from the long experience as therapeutic agents. Both are 
old drugs, and therefore, the safety profile and side effects are well 
known. In this context, we can state that if they are proven effective 
in tumoral cases difficult to manage, the therapeutic solution may 
be immediate from the bench to the patient. In our case, after 4 
months taking propranolol as the only medication, the improvement 
is maintained, which would support the use of propranolol as a drug 
that significantly increases the progression-free survival in absence 
of temozolomide. If these results are confirmed in more studies, its 
use would represent an advantage, allowing - once the disease is 
in remission - periods of time for the marrow to recover from the 
adverse effects of chemotherapy with the alkylating agent.
The strengths of the treatment are the results and the absence of 
serious side effects for the propranolol in this particular case. The 
limitations of using propranolol derive from the anti-hypertensive 
effects. Hypotensive patients should take care with the treatment, 
and be always under cardiologist supervision.
For these rare diseases where therapeutic options are scarce and 
with not very successful results, outcomes like the one reported 
here have to be seriously considered if we want to improve the qual-
ity and life expectancy for these - in most cases - young patients.
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